MD Anderson Orlando receives donation to fight against pancreatic cancer

Jan 17 2012

MD Anderson Cancer Center Orlando has received a generous donation to help in the fight against pancreatic cancer. A $75,000 grant, funded by the Shirley E. Noland Foundation, will support the Pancreatic Cancer Translational Research Project at MD Anderson - Orlando. The project will take the latest research findings to develop new treatment programs for patients with pancreatic cancer. The project will focus on testing tolfenamic acid (a drug commonly used in Europe to treat migraine headaches), to inhibit the growth of human pancreatic cancer cells and improve the chance of surviving this type of cancer. Last year the Shirley E. Noland Foundation funded preclinical research at MD Anderson - Orlando for a Phase 1 Clinical Trial for pancreatic cancer using tolfenamic acid.

"We are truly grateful to move our pancreatic cancer program forward with the continued support of the Shirley E. Noland Foundation," said Clarence Brown, MD, President and CEO of MD Anderson - Orlando. "Treating pancreatic cancer poses unique challenges because so often by the time this type of cancer is detected, it has already spread. These dollars will help us fight this type of cancer by opening new doors for our researchers and oncologists as they work to beat this disease. Ultimately, this donation will save lives. "